Bringing Equity and Efficacy Together in Triple-Negative Breast Cancer: A Practical Guide for the Oncology Nurse

February 10, 2022

This Oncology Nursing Society (ONS) Chapter initiative is targeted to oncology nurses and nurse practitioners, specifically those practicing in the southeastern United States. Strategically designed to foster an understanding of both the disease state complexity and far-reaching racial disparity intrinsic to triple-negative breast cancer (TNBC), this educational session will begin with an appraisal of TNBC pathophysiology and the multifaceted etiologies of the disparate outcomes seen among African-American patients. Expert faculty will then guide attendees through a real-world exploration of antibody-drug conjugates, including structure, mechanism of action, and a dedicated focus on the effective anticipation, recognition, and mitigation of adverse events. Finally, attendees will take part in an interactive case-based discussion centered on how the oncology nurse can provision patient-centric care that is both efficacious and equitable through the incorporation of novel therapeutic approaches and the adoption of renewed perspectives.


 

Target Audience

Oncology Nurse Specialists, Registered Nurses, Nurse Practitioners

Learning Objectives

  • Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies oncology nurses can employ to promote equitable care and outcomes for all patients.
  • Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, with a particular focus on toxicity management, for oncology nurses who care for TNBC patients receiving ADCs.
  • Examine completed, ongoing, and planned clinical trial data for ADCs as part of the expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
  • Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus, strategies for anticipating, recognizing, and treating adverse events, and effectively integrating socioeconomic and other non-biologic factors into equitable cancer care.

Supported through an independent educational grant from Gilead.

Presented by Creative Educational Concepts, Inc.

Additional Information

AttachmentSize
PDF icon Handout & References2.9 MB
PDF icon General Information734.21 KB
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
12/20/2021
Course expires: 
02/28/2022
Event starts: 
02/10/2022 - 6:30pm EST
Event ends: 
02/10/2022 - 7:30pm EST
Rating: 
0

5 min     Welcome and Introductions/Pre-test

15 min   Delineating the Disparity in TNBC: A Renewed Outlook on an Established Problem

20 min   Demystifying Antibody-Drug Conjugates: The Role of the Oncology Nurse in the Evolving TNBC

              Paradigm

15 min   Closing the TNBC Outcomes Chasm: Nursing Perspectives on Novel Therapeutics and Patient-

              Centered Care

5 min     Conversations with the Experts/Audience Q&A/Post-test

Virtual Live Event
Columbus, OH
6:30PM ET
United States

Jennifer A. McKenna, NP
Acute Care Nurse Practitioner
Dana-Farber
Brigham and Woman's Cancer Center's
Breast Oncology Program
Boston, MA

 

 

 

Jennifer is a nurse practitioner in the breast oncology unit at Dana Farber Cancer Institute. She trained at Yale School of Nursing as an acute care NP with a focus in oncology. She has been in practice for 20 years.


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Jennifer A. McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:
Jennifer A. McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Elahe Salehi, DNP, ANP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.

Reviewer:
Lauren Olalde, RN–is on the speakers' bureau for Trodelvy.  

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

 

Available Credit

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.